Compare AbbVie Inc (ABBV) vs Walt Disney Co (DIS) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Disney (DIS) trades at $97.41, down 2.06% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $1.88. Revenue growth has accelerated from $82.7B in 2022 to $94.4B in 2025, while net income surged to $12.4B. Analyst consensus remains strongly bullish with a $131.89 price target, representing 35% upside potential from current levels.

Disney presents a compelling investment case with improving profitability and strong cash flow generation, though regulatory challenges and recent box office disappointments pose near-term risks. The stock's current valuation at 15.59x P/E appears attractive relative to growth prospects, while technical indicators suggest potential support near $94-96 levels.